Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review ; volume:16 ; number:1 ; day:27 ; month:4 ; year:2024 ; pages:1-13 ; date:12.2024
Alzheimer's research & therapy ; 16, Heft 1 (27.4.2024), 1-13, 12.2024
- Creator
-
Oosthoek, Marlies
Vermunt, Lisa
Wilde, Arno de
Bongers, Bram
Antwi-Berko, Daniel
Scheltens, Philip
Bokhoven, Pieter van
Vijverberg, Everard G. B.
Teunissen, Charlotte E.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-024-01456-1
- URN
-
urn:nbn:de:101:1-2407111546004.491875312904
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Oosthoek, Marlies
- Vermunt, Lisa
- Wilde, Arno de
- Bongers, Bram
- Antwi-Berko, Daniel
- Scheltens, Philip
- Bokhoven, Pieter van
- Vijverberg, Everard G. B.
- Teunissen, Charlotte E.
- SpringerLink (Online service)
Other Objects (12)
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
The “rights” of precision drug development for Alzheimer’s disease
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The plasma peptides of Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Disease-modifying treatments in Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum
Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
The “rights” of precision drug development for Alzheimer’s disease
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The plasma peptides of Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Disease-modifying treatments in Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum
Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
The “rights” of precision drug development for Alzheimer’s disease
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The plasma peptides of Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Disease-modifying treatments in Alzheimer’s disease
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Plasma oligomer beta-amyloid is associated with disease severity and cerebral amyloid deposition in Alzheimer’s disease spectrum